» Articles » PMID: 7231514

Scintigraphic Localization of Pheochromocytoma

Overview
Journal N Engl J Med
Specialty General Medicine
Date 1981 Jul 2
PMID 7231514
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

We used a new radiopharmaceutical agent, [131I]meta-iodobenzylguanidine ([131I]MIBG), to produce scintigraphic images of pheochromocytomas in eight patients. One day or more after injection, the only normal organ that displayed distinct concentrations of radioactivity was the urinary bladder. The [131I]MIBG was probably concentrated in adrenergic vesicles; in tissues where vesicles are numerous, such as pheochromocytomas, the radionuclide was retained for days. The spectrum of pheochromocytomas shown the scintigrams was broad: intra-adrenal and extraadrenal in location, benign and malignant in character, 0.2 to 65 g in weight, and with different hormone patterns in secretion. Tumors in four patients were not detected by computed tomography. In one patient, reoperation was undertaken only because the scintigram located the extra-adrenal tumors and thereby directed the surgeon's exploration. The method offers hope of safe and reliable localization of pheochromocytomas in their many guises.

Citing Articles

Peptide Receptor Radionuclide Therapy.

Hofland J, Brabander T, Verburg F, Feelders R, de Herder W J Clin Endocrinol Metab. 2022; 107(12):3199-3208.

PMID: 36198028 PMC: 9693835. DOI: 10.1210/clinem/dgac574.


Nonclinical study and applicability of the absorbed dose conversion method with a single biodistribution measurement for targeted alpha-nuclide therapy.

Sakashita T, Matsumoto S, Watanabe S, Hanaoka H, Ohshima Y, Ikoma Y EJNMMI Phys. 2021; 8(1):80.

PMID: 34897556 PMC: 8665908. DOI: 10.1186/s40658-021-00425-z.


Imaging pheochromocytoma in small animals: preclinical models to improve diagnosis and treatment.

Mohr H, Foscarini A, Steiger K, Ballke S, Rischpler C, Schilling F EJNMMI Res. 2021; 11(1):121.

PMID: 34894301 PMC: 8665914. DOI: 10.1186/s13550-021-00855-x.


High-specific-activity iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

Dillon J, Bushnell D, Laux D Future Oncol. 2021; 17(10):1131-1141.

PMID: 33506713 PMC: 7927907. DOI: 10.2217/fon-2020-0625.


Human dosimetry of free At and meta-[At]astatobenzylguanidine (At-MABG) estimated using preclinical biodistribution from normal mice.

Ukon N, Zhao S, Washiyama K, Oriuchi N, Tan C, Shimoyama S EJNMMI Phys. 2020; 7(1):58.

PMID: 32960387 PMC: 7509022. DOI: 10.1186/s40658-020-00326-7.